Targeting mutant p53 in cancer: a long road to precision therapy.

@article{Mantovani2017TargetingMP,
  title={Targeting mutant p53 in cancer: a long road to precision therapy.},
  author={Fiamma Mantovani and Dawid Walerych and Giannino Del Sal},
  journal={The FEBS journal},
  year={2017},
  volume={284 6},
  pages={837-850}
}
The TP53 tumor suppressor is the most frequently mutated gene in human cancers. In recent years, a blooming of research efforts based on both cell lines and mouse models have highlighted how deeply mutant p53 proteins affect fundamental cellular pathways with cancer-promoting outcomes. Neomorphic mutant p53 activities spread over multiple levels, impinging on chromatin structure, transcriptional regulation and microRNA maturation, shaping the proteome and the cell's metabolic pathways, and also… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…